SEC Form 4 · accession 0001562180-19-000087
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A. Velleca
Officer — President and CEO · Director
Period of report
Jan 2, 2019
Accepted (ET)
Jan 2, 2019 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $19.56 | Jan 2, 2019 | A | 225,000 | A | — | Jan 2, 2029 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.